Changeflow GovPing Healthcare & Life Sciences Mediterranean Diet Study, Type 1 Diabetes, Oxid...
Routine Notice Added Final

Mediterranean Diet Study, Type 1 Diabetes, Oxidative Stress

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

ClinicalTrials.gov registered a new observational/interventional study (NCT07544368) examining the effect of a 12-week Mediterranean diet on oxidative stress markers in girls aged 10-18 years with type 1 diabetes who do not meet the metabolic target (HbA1c > 7%). The study is planned between March 2026 and March 2027 and will be conducted at the Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University. Participants in the intervention group will receive Mediterranean diet adherence guidance and monitoring over the 12-week period.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 676 changes logged to date.

What changed

NIH registered a clinical trial on ClinicalTrials.gov investigating whether a 12-week Mediterranean diet intervention reduces oxidative stress in pediatric type 1 diabetes patients with suboptimal glycemic control (HbA1c > 7%) and poor Mediterranean diet adherence. Participants were identified using the KIDMED pediatric Mediterranean diet adherence scale and HbA1c levels, with the intervention group (Group C) receiving dietary counseling over 12 weeks.

Healthcare providers and researchers conducting pediatric diabetes studies should note this registration reflects growing interest in nutritional interventions as adjunct therapies in type 1 diabetes management. The study's focus on metabolic target achievement and oxidative stress markers may inform future clinical guidance on medical nutrition therapy for this population.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

MEDITERRANEAN DIET AND OXIDATIVE STRESS IN TYPE 1 DIABETES

N/A NCT07544368 Kind: NA Apr 22, 2026

Abstract

Achieving optimal glycemic control in type 1 diabetes requires a holistic approach that includes individualized medical nutrition therapy in addition to appropriate insulin therapy. When diabetes is poorly managed, metabolic control is impaired. Hyperglycemic events increase oxidative stress in the body and can lead to complications. The aim of this study is to examine the effect of a 12-week Mediterranean diet on oxidative stress markers in children with type 1 diabetes who do not meet the metabolic target (HbA1c > 7%) and whose adherence to the Mediterranean diet is "poor" and "needs improvement".

The study, planned between March 2026 and March 2027, will be conducted with girls aged 10-18 years with type 1 diabetes who are followed up at the Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University. In the first phase, participants were divided into groups based on their HbA1c levels: those with HbA1c ≤ 7 met the metabolic target (Group A); Those with HbA1c > 7 will be divided into two groups: those not meeting the metabolic target (Group B). In the second stage, the intervention group will be determined according to the results of the KIDMED, the pediatric Mediterranean diet adherence scale. Those in Group B who did not meet the metabolic targets and those with "poor" and "need improvement" KIDMED results will form the intervention group (Group C). Adolescents in Group C will receive a 12-week Mediterranean diet intervention. Informati...

Conditions: Type 1 Diabetes (Juvenile Onset), Continuous Glucose Monitoring System, Oxidative Stress

Interventions: Mediterranean Diet Intervention

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 22nd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07544368

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Medical research Nutrition intervention
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!